Lupeol, A Novel Fuit and Vegetable Based Triterpene for Prostate Cancer

羽扇豆醇,一种治疗前列腺癌的新型水果和植物三萜

基本信息

  • 批准号:
    7472599
  • 负责人:
  • 金额:
    $ 7.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-08-01 至 2010-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): It is estimated that 234,460 new prostate cancer cases will be diagnosed and approximately 27,350 prostate cancer-related deaths are predicted in the US alone in the year 2006. Persistence of isolated cancer cells (even after surgery and androgen-ablation therapy), their proliferation, androgen-independence and invasion to distant sites is the major cause of deaths in human prostate cancer patients. Aberration in the levels and functioning of multiple proteins or molecular pathways including beta catenin, nuclear factor kappa B and phosphotidyl inositol 3 kinase /Akt signaling network, has been associated with the androgen-independence, proliferation, invasion and chemoresistance of prostate cancer cells. Since most of the chemotherapeutic agents generally target a specific protein or a molecular pathway, they most often fail to inhibit the growth of advanced prostate cancer in preclinical and clinical settings. Thus, it is important to identify novel agents with an ability to target multiple molecular pathways. It is increasingly appreciated that chemoprevention through diet-based natural agents could be an effective approach to prevent and treat prostate cancer in humans. Based on our published studies and preliminary data, we believe that Lupeol, a non-nutrient and non-toxic natural agent present in strawberry, grapes, mango, figs, olive and vegetables, could be an ideal chemopreventive and therapeutic agent with an ability to act on multiple molecular pathways. We hypothesize that Lupeol has the potential to kill highly aggressive and chemoresistant prostate cancer cells while sparing normal cells, inhibit their proliferation and invasion through the modulation of beta catenin, nuclear factor kappa B and phosphotidyl inositol 3 kinase /Akt signaling network. It is important to emphasize that, consistent with current NCI opinion, the term "chemoprevention" is used in its broadest sense in this application, i.e. in a partially therapeutic as well as purely preventive context. To achieve our goal, we propose two specific aims: (1) to investigate the anti-proliferative potential of Lupeol against androgen-independent prostate cancer cells, and to define its mechanism of action under cell culture conditions and (2) to investigate whether Lupeol possesses the chemopreventive and/or chemotherapeutic effects against the tumorigenicity of androgen-insensitive prostate cancer cells in an animal model. We believe that this application will be extremely valuable in providing a novel fruit and vegetable based agent for chemoprevention and possibly for treating prostate cancer
描述(由申请人提供): 据估计,2006年仅在美国就将诊断出234,460例新的前列腺癌病例,预计约有27,350例前列腺癌相关死亡。分离的癌细胞的持续存在(即使在手术和雄激素消融治疗后)、它们的增殖、雄激素非依赖性和向远处部位的侵袭是人类前列腺癌患者死亡的主要原因。包括β连环蛋白、核因子κ B和磷脂酰肌醇3激酶/Akt信号传导网络在内的多种蛋白质或分子通路的水平和功能的异常与前列腺癌细胞的雄激素非依赖性、增殖、侵袭和化疗耐药性相关。由于大多数化学治疗剂通常靶向特定的蛋白质或分子途径,因此它们在临床前和临床环境中通常不能抑制晚期前列腺癌的生长。因此,重要的是鉴定具有靶向多个分子途径的能力的新型药剂。越来越多的人认识到,通过饮食为基础的天然药物的化学预防可能是一种有效的方法来预防和治疗人类前列腺癌。根据我们已发表的研究和初步数据,我们相信羽衣甘蓝醇是一种存在于草莓、葡萄、芒果、无花果、橄榄和蔬菜中的无营养、无毒的天然物质,可能是一种理想的化学预防和治疗剂,具有作用能力作用于多个分子途径。我们推测羽扇豆醇可能通过调节β-连环蛋白、核因子κ B和磷脂酰肌醇3激酶/Akt信号网络,杀死高侵袭性和化疗耐药的前列腺癌细胞,同时保护正常细胞,抑制其增殖和侵袭。重要的是要强调,与目前NCI的意见一致,术语“化学预防”在本申请中以其最广泛的意义使用,即在部分治疗以及纯粹预防的情况下。为了实现我们的目标,我们提出了两个具体的目标:(1)调查羽扇豆醇对雄激素非依赖性前列腺癌细胞的抗增殖潜力,并确定其在细胞培养条件下的作用机制和(2)调查羽扇豆醇是否具有对雄激素不敏感的前列腺癌细胞在动物模型中的致瘤性的化学预防和/或化疗效果。我们相信,这种应用将是非常有价值的,在提供一种新的水果和蔬菜为基础的化学预防剂,并可能用于治疗前列腺癌

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene.
  • DOI:
    10.1016/j.canlet.2009.04.033
  • 发表时间:
    2009-11-28
  • 期刊:
  • 影响因子:
    9.7
  • 作者:
    Saleem, Mohammad
  • 通讯作者:
    Saleem, Mohammad
Androgen receptor in human health: a potential therapeutic target.
  • DOI:
    10.2174/138945012804545579
  • 发表时间:
    2012-11
  • 期刊:
  • 影响因子:
    3.2
  • 作者:
    Hifzur R Siddique;S. Nanda;A. Parray;M. Saleem
  • 通讯作者:
    Hifzur R Siddique;S. Nanda;A. Parray;M. Saleem
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mohammad Saleem Bhat其他文献

Mohammad Saleem Bhat的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mohammad Saleem Bhat', 18)}}的其他基金

Novel targeted chemo/immunotherapy approach for localized and metastatic CaP
针对局部和转移性 CaP 的新型靶向化疗/免疫治疗方法
  • 批准号:
    10415649
  • 财政年份:
    2021
  • 资助金额:
    $ 7.35万
  • 项目类别:
Novel gene that determines metastatic phenotype in African-American men with PCa
决定非裔美国前列腺癌​​男性转移表型的新基因
  • 批准号:
    9103022
  • 财政年份:
    2015
  • 资助金额:
    $ 7.35万
  • 项目类别:
Delaying the Hormone Refractory Prostate Cancer by a Dietary Triterpene Lupeol
通过膳食三萜羽扇豆醇延缓激素难治性前列腺癌的发生
  • 批准号:
    7835621
  • 财政年份:
    2009
  • 资助金额:
    $ 7.35万
  • 项目类别:
Delaying the Hormone Refractory Prostate Cancer by a Dietary Triterpene Lupeol
通过膳食三萜羽扇豆醇延缓激素难治性前列腺癌的发生
  • 批准号:
    7661136
  • 财政年份:
    2009
  • 资助金额:
    $ 7.35万
  • 项目类别:
Lupeol, A Novel Fuit and Vegetable Based Triterpene for Prostate Cancer
羽扇豆醇,一种治疗前列腺癌的新型水果和植物三萜
  • 批准号:
    7321036
  • 财政年份:
    2007
  • 资助金额:
    $ 7.35万
  • 项目类别:

相似海外基金

Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
  • 批准号:
    DP230103210
  • 财政年份:
    2023
  • 资助金额:
    $ 7.35万
  • 项目类别:
    Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
  • 批准号:
    10584689
  • 财政年份:
    2023
  • 资助金额:
    $ 7.35万
  • 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
  • 批准号:
    10650956
  • 财政年份:
    2023
  • 资助金额:
    $ 7.35万
  • 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
  • 批准号:
    10488954
  • 财政年份:
    2023
  • 资助金额:
    $ 7.35万
  • 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
  • 批准号:
    10651105
  • 财政年份:
    2023
  • 资助金额:
    $ 7.35万
  • 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
  • 批准号:
    10603636
  • 财政年份:
    2023
  • 资助金额:
    $ 7.35万
  • 项目类别:
Androgen receptor function in melanoma
雄激素受体在黑色素瘤中的功能
  • 批准号:
    10416658
  • 财政年份:
    2022
  • 资助金额:
    $ 7.35万
  • 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
  • 批准号:
    10544062
  • 财政年份:
    2022
  • 资助金额:
    $ 7.35万
  • 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
  • 批准号:
    10534943
  • 财政年份:
    2022
  • 资助金额:
    $ 7.35万
  • 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
  • 批准号:
    10677989
  • 财政年份:
    2022
  • 资助金额:
    $ 7.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了